Please login to the form below

Not currently logged in
Email:
Password:

MYSTIC trial

This page shows the latest MYSTIC trial news and features for those working in and with pharma, biotech and healthcare.

AZ still sees route to approval for Imfinzi in MYSTIC trial

AZ still sees route to approval for Imfinzi in MYSTIC trial

expand and tweak the protocol of its ongoing NEPTUNE trial of Imfinzi with tremelimumab in first-line NSCLC that is due to generate results early next year. ... month and it is hard to explain why the duo performed worse than Imfinzi on its own in MYSTIC.

Latest news

More from news
Approximately 1 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    The NELSON trial, which looked at screening in Europe, was presented at the recent World Conference on Lung Cancer. ... However, recent overall survival results from the MYSTIC trial, which studied Imfinzi with CTLA4 inhibitor tremelimumab, have just

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    Open-minded culture. Like the new HQ’s construction, there have been setbacks – such as the setback to its Imfinzi tremelimumab immunotherapy combination in the MYSTIC lung cancer trial last year –

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics